MedTrace Logo

Stress Urinary Incontinence Study to Assess Safety and Efficacy of Muvon's Muscle Precursor Cell Therapy

NCT05534269 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-08

No results posted yet for this study

Summary

The objective of the SUISSE MPC 2 study is to treat stress urinary incontinence in adult women.

Conditions

  • Female Stress Urinary Incontinence

Interventions

BIOLOGICAL

autologous muscle precursor cells

Patients own Muscle Precursor Cells are isolated and injected into the rhabdomyosphincter

Sponsors & Collaborators

  • GCP-Service International Ltd. & Co. KG

    collaborator INDUSTRY

  • University of Zurich

    lead OTHER

Principal Investigators

  • Tobias Schmidli, MD · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2025-07-14
Completion
2025-07-14

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05534269 on ClinicalTrials.gov